Sign In
Buy BIXT
$0.0238
+0.0020 (+8.95%)
At Close: Jul 31, 2026
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
09:00am, Thursday, 07'th Aug 2025
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
10:50am, Wednesday, 18'th Jun 2025
- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, I
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
09:12am, Tuesday, 03'rd Jun 2025
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments
Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission
09:00am, Wednesday, 21'st May 2025
PHM23 was one of a handful of molecules chosen by the university Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSW
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
09:00am, Monday, 12'th May 2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
09:30am, Friday, 11'th Apr 2025
- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
09:30am, Wednesday, 19'th Mar 2025
In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinica
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
09:30am, Wednesday, 12'th Mar 2025
New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks
Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10:21am, Friday, 10'th Jan 2025
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral
Bioxytran's Medical Breakthrough in Fighting All Viruses
09:35am, Thursday, 19'th Sep 2024
Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
09:00am, Thursday, 18'th Jul 2024
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a
Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients
01:09pm, Thursday, 27'th Jun 2024
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
09:00am, Wednesday, 06'th Mar 2024
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical
Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
08:00am, Wednesday, 21'st Feb 2024
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT ), (the “Company”), a clinical stage biotechno
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
08:45am, Tuesday, 24'th Oct 2023
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical st
